Kamada Ltd. KMDA

Company Overview

Kamada Ltd. is an Israel-based biopharmaceutical company focused on the development, manufacturing, and commercialization of specialty plasma-derived therapeutics. The company operates primarily in the biopharmaceutical and specialty therapeutics industries, with a concentration on immune globulin-based products, plasma collection, and specialty biologics used for rare and serious conditions. Kamada’s revenue is generated through proprietary product sales, distribution agreements, plasma collection activities, and contract manufacturing services.

The company’s core business lines include specialty plasma-derived therapeutics such as Glassia, an intravenous Alpha-1 Antitrypsin (AAT) therapy for Alpha-1 Antitrypsin Deficiency, as well as rabies immune globulin and other immunoglobulin products. Kamada also operates plasma collection centers in the United States and distributes several specialty products through strategic partnerships. Founded in 1990 in Israel, Kamada evolved from a plasma-derived therapeutics developer into a vertically integrated biopharmaceutical company with commercial operations across multiple international markets. Its strategic positioning is supported by specialized plasma expertise, regulatory-approved manufacturing capabilities, and long-term partnerships with larger pharmaceutical companies.

Business Operations

Kamada conducts operations through several principal activities, including Commercial Products, Plasma Collection, and contract manufacturing and development services. The company derives revenue from sales of proprietary therapeutics, distribution of third-party specialty products, plasma collection operations, and technology transfer or manufacturing agreements. Its plasma-derived therapeutics manufacturing infrastructure is centered in Israel, while plasma collection operations are largely based in the United States through subsidiaries operating FDA-licensed plasma collection centers.

The company maintains international commercial activities through direct sales and strategic collaborations. Kamada has historically partnered with larger pharmaceutical companies for distribution and commercialization of certain products, including arrangements related to Glassia in the United States. The company also controls specialized manufacturing technologies associated with plasma fractionation and purification processes. Subsidiaries associated with plasma collection and specialty therapeutics operations form a significant part of Kamada’s operating model, supporting vertical integration between raw plasma sourcing and finished biologic production.

Strategic Position & Investments

Kamada’s strategic direction has focused on expanding its portfolio of specialty plasma-derived products, increasing recurring revenues from commercialized therapies, and strengthening its plasma supply chain. The company has invested in expanding its U.S.-based plasma collection network to support manufacturing capacity and reduce dependence on third-party plasma suppliers. Growth initiatives have also included geographic expansion for approved products and development of additional indications for existing therapies.

The company has pursued acquisitions and strategic investments aimed at strengthening its specialty therapeutics and plasma infrastructure capabilities. Kamada has also increased emphasis on distributed products and partnerships that broaden its commercial portfolio beyond internally developed products. Emerging areas of interest include specialty immunoglobulin therapies and biologics targeting rare diseases and immune-related conditions. The company’s operational model combines proprietary product development with commercial partnerships designed to enhance market access and long-term revenue stability.

Geographic Footprint

Kamada is headquartered in Rehovot, Israel, and maintains operational and commercial activities across multiple regions, including North America, Europe, Latin America, Asia-Pacific, and the Middle East. The company’s manufacturing operations are primarily located in Israel, while its plasma collection business is concentrated in the United States, which represents one of its most important commercial markets.

The company markets and distributes products internationally through direct operations, licensing agreements, and strategic distribution partnerships. Kamada’s plasma collection footprint in the United States supports both domestic and international supply needs for plasma-derived therapies. Its products have received approvals from several international regulatory authorities, enabling commercial access across multiple healthcare systems and specialty treatment markets.

Leadership & Governance

Kamada was founded by David Tsur, who played a central role in establishing the company’s plasma-derived therapeutics platform and early commercialization strategy. The company is publicly traded on Nasdaq under the ticker KMDA and operates under a governance structure that includes executive leadership with experience in biopharmaceutical operations, manufacturing, commercialization, and finance. Management strategy has emphasized operational discipline, vertical integration in plasma sourcing, and expansion of specialty therapeutics markets.

Key executives include:

• Amir London – Chief Executive Officer
• Ran Oren – Chief Financial Officer
• Dr. Daphne Tishler – Senior Vice President, Research & Development and Chief Scientific Officer
• Yaron Kalberman – Chief Operating Officer
• Erez Tsalik – Chief Commercial Officer

The company’s leadership philosophy has centered on expanding sustainable profitability through specialty biologics commercialization, operational efficiency, and strategic partnerships in regulated global healthcare markets.